Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8321930 | The International Journal of Biochemistry & Cell Biology | 2018 | 9 Pages |
Abstract
In this study, we showed that activation of nuclear factor-κB (NF-κB) is significantly higher in therapy-resistant EOC cells compared to chemosensitive counterparts, which was positively associated with resistance to cisplatin, carboplatin, paclitaxel and erlotinib. Bay 11-7082, a highly selective NF-κB inhibitor, reduced cell proliferation, clonogenicity and anoikis resistance in the therapy-resistant EOC cells and induced apoptotic cell death. Moreover, Bay 11-7082 decreased the expression of pro-survival, inflammatory and metastatic genes and synergistically increased anti-proliferative efficacy of cisplatin, carboplatin, paclitaxel and erlotinib. Altogether, these findings suggest that NF-κB is an attractive therapeutic target in EOC to be exploited in translational oncology and Bay 11-7082 is a potential anti-cancer drug to overcome chemoresistance and inhibit proliferation of the EOC cells.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Majid Momeny, Hassan Yousefi, Haniyeh Eyvani, Farima Moghaddaskho, Ali Salehi, Fatemeh Esmaeili, Zivar Alishahi, Farinaz Barghi, Somaye Vaezijoze, Sahar Shamsaiegahkani, Ghazaleh Zarrinrad, Ghazaleh Sankanian, Zahra Sabourinejad, Sepideh Hamzehlou,